234 related articles for article (PubMed ID: 22322592)
1. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
[TBL] [Abstract][Full Text] [Related]
3. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
4. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
Murakawa Y; Sakayori M; Otsuka K
BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
6. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.
Ludbrook JJ; Truong PT; MacNeil MV; Lesperance M; Webber A; Joe H; Martins H; Lim J
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1321-30. PubMed ID: 12654444
[TBL] [Abstract][Full Text] [Related]
7. Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer Outcomes.
Rittberg R; Green S; Aquin T; Bucher O; Banerji S; Dawe DE
Clin Lung Cancer; 2020 Sep; 21(5):e388-e404. PubMed ID: 32197856
[TBL] [Abstract][Full Text] [Related]
8. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.
Christodolou C; Pavlidis N; Samantas E; Fountzilas G; Kouvatseas G; Pagdatoglou K; Palamidas F; Nikolaidis C; Angelidou M; Kalofonos HP; Kosmidis P; Skarlos DV
Anticancer Res; 2002; 22(6B):3749-57. PubMed ID: 12552988
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy.
Saruwatari K; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ohe Y; Goto K
Clin Lung Cancer; 2016 Nov; 17(6):581-587. PubMed ID: 27424806
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
[TBL] [Abstract][Full Text] [Related]
13. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
15. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute.
Chute JP; Venzon DJ; Hankins L; Okunieff P; Frame JN; Ihde DC; Johnson BE
Mayo Clin Proc; 1997 Oct; 72(10):901-12. PubMed ID: 9379691
[TBL] [Abstract][Full Text] [Related]
17. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
18. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.
Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen J; Gitlitz B; Mack PC; Gandara DR
Clin Lung Cancer; 2016 Mar; 17(2):113-8.e1-2. PubMed ID: 26498504
[TBL] [Abstract][Full Text] [Related]
19. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
20. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
